全球盆腔蜂窝织炎治疗市场 – 行业趋势和 2029 年预测

市场分析和规模

近年来，盆腔蜂窝织炎治疗市场预计在预测期内将快速增长。尽管大多数患者就诊时都伴有腹部症状或败血症症状，但腹腔内脓肿的临床表现范围很广。持续的胃痛/压痛、腹胀、肿块或肠梗阻都是可能的症状。恶心、厌食和体重减轻也很常见。盆腔蜂窝织炎是一种炎症性、充满液体的肿块，可能发生在女性盆腔中。细菌渗入阴道上部，引起脓肿。细菌通常来自不同的生殖道疾病，例如盆腔炎 (PID)，或来自下生殖道的细菌通过宫颈向上传播。男性盆腔蜂窝织炎极为罕见，即使发生，它们通常也会生长在前列腺上方。它们在女性中更常见。所有这些因素导致市场对盆腔蜂窝织炎治疗的需求很高。   

Data Bridge Market Research 分析称，2021 年盆腔蜂窝织炎治疗市场价值为 3.7891 亿美元，预计到 2029 年将达到 5.3065 亿美元，在 2022 年至 2029 年的预测期内复合年增长率为 4.30%。Data Bridge Market Research 团队策划的市场报告包括深入的专家分析、患者流行病学、管道分析、定价分析和监管框架。

市场定义

盆腔蜂窝织炎通常被称为盆腔脓肿。盆腔蜂窝织炎最常见的病因包括急性阑尾炎、妇科疾病和手术。它也可能作为克罗恩病、憩室炎或腹部手术的副作用而发生。脓肿是被炎性组织包裹的感染脓液或液体的集合。盆腔脓肿在发病或出现明显症状之前可以长得相当大，因此很容易被发现。脓肿通常用抗生素治疗，并引流脓肿。在小脓肿的早期阶段，单独使用抗生素是有益的。

报告范围和市场细分

Pelvic Cellulitis Treatment Market Dynamics

Drivers

• Increasing prevalence of pelvic inflammatory disease (PID)

The pelvic cellulitis treatment market is driven by an increase in prevalence of pelvic inflammatory disease (PID).

• Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of pelvic cellulitis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the pelvic cellulitis treatment market. Additionally, high disposable income and rising demand for advanced treatment and innovative solutions will result in the expansion of pelvic cellulitis treatment market. Along with this, rising geriatric population and changing lifestyle of people will enhance the growth rate of the market.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the pelvic cellulitis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the pelvic cellulitis treatment market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of pelvic cellulitis treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the pelvic cellulitis treatment market. Additionally, lack of awareness and strict regulatory framework that delays the approval of products will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This pelvic cellulitis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the pelvic cellulitis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

An abscess develops in less than 1% of patients undergoing obstetric or gynecologic surgery. 783 (3%) of 23,366 patients who had a laparoscopic or abdominal hysterectomy had a surgical site infection, according to a retrospective cohort study. The majority of these infections were wound infections, but around a quarter of them were infections of the organ space.

Pelvic cellulitis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Pelvic Cellulitis Treatment Market

Since its emergence in December 2019, the COVID-19 virus has spread to nearly every country on the planet, prompting the World Health Organization (WHO) to declare it a public health emergency. Due to the financial crisis and the delay in specialty healthcare delivery, while prioritizing COVID-19-related treatments, healthcare systems around the world have been severely disrupted in the aftermath of the coronavirus pandemic. Patients were unable to see their controls for a variety of reasons, including difficulty accessing a doctor, fear of infection transmission, and inability to continue therapies and essential procedures due to pandemic restrictions. Such considerations may have a negative impact on the market of pelvic cellulitis treatment in recent months.

Recent Development

• In July 2020, Endo International plc had announced the launch of Qwo (collagenase clostridium histolyticum-aaes) with U.S. Food and Drug Administration (FDA) approval. QWO is a type of prescription drug that is used for the treatment of moderate to severe cellulite in the buttocks of adult women.

Global Pelvic Cellulitis Treatment Market Scope

The pelvic cellulitis treatment market is segmented on the basis of diagnosis, treatment, dosage, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Diagnosis

• Ultrasound
• Laparoscopy
• CT scan
• Endoscopic Ultrasound
• Others

On the basis of diagnosis, the pelvic cellulitis treatment market is segmented into ultrasound, laparoscopy, CT scan, endoscopic ultrasound and others.

Treatment

• Antibiotics
• Others

On the basis of treatment, the pelvic cellulitis treatment market is segmented into antibiotics and others.

Dosage

• Tablet
• Injection
• Others

On the basis of dosage, the pelvic cellulitis treatment market is segmented into tablet, injection and others.

Route of Administration

• Oral
• Intravenous
• Others

The route of administration segment for the pelvic cellulitis market is segmented into oral, intravenous and others.

 End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

On the basis of end-users, the pelvic cellulitis treatment market is segmented into hospitals, specialty clinics, homecare and others.

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

On the basis of distribution channel, the pelvic cellulitis treatment market has also been segmented into hospital pharmacy, retail pharmacy, online pharmacy and others

Pelvic Cellulitis Treatment Market Regional Analysis/Insights

The pelvic cellulitis treatment market is analysed and market size insights and trends are provided by country, diagnosis, treatment, dosage, route of administration, end-users and distribution channel as referenced above.

盆腔蜂窝织炎治疗市场报告涵盖的国家包括北美洲的美国、加拿大和墨西哥、欧洲的德国、法国、英国、荷兰、瑞士、比利时、俄罗斯、意大利、西班牙、土耳其、欧洲其他地区、中国、日本、印度、韩国、新加坡、马来西亚、澳大利亚、泰国、印度尼西亚、菲律宾、亚太地区 (APAC) 的其他地区、沙特阿拉伯、阿联酋、南非、埃及、以色列、中东和非洲 (MEA) 的其他地区、南美洲的巴西、阿根廷和南美洲其他地区

北美在盆腔蜂窝织炎治疗市场占据主导地位，因为该地区存在主要关键参与者，且盆腔蜂窝织炎患病率不断上升。

由于医疗保健支出增加和患者数量增加，预计亚太地区在 2022 年至 2029 年的预测期内将实现增长。

报告的国家部分还提供了影响单个市场因素和国内市场监管变化，这些因素和变化会影响市场的当前和未来趋势。下游和上游价值链分析、技术趋势和波特五力分析、案例研究等数据点是用于预测单个国家市场情景的一些指标。此外，在提供国家数据的预测分析时，还考虑了全球品牌的存在和可用性以及它们因来自本地和国内品牌的激烈或稀缺竞争而面临的挑战、国内关税和贸易路线的影响。   

竞争格局和盆腔蜂窝织炎治疗市场份额分析

盆腔蜂窝织炎治疗市场竞争格局按竞争对手提供详细信息。详细信息包括公司概况、公司财务状况、产生的收入、市场潜力、研发投资、新市场计划、全球影响力、生产基地和设施、生产能力、公司优势和劣势、产品发布、产品宽度和广度、应用主导地位。以上提供的数据点仅与公司对盆腔蜂窝织炎治疗市场的关注有关。

盆腔蜂窝织炎治疗市场的一些主要参与者包括：

• 艾尔建（爱尔兰）
• 默克公司（美国）
• 住友公司（日本）
• 辉瑞公司（美国）
• 葛兰素史克公司 (英国)
• Melinta Therapeutics LLC（美国）
• 巴塞利亚制药有限公司 (瑞士)
• Tetraphase Pharmaceuticals（美国）
• Paratek Pharmaceuticals, Inc.（美国）
• Nabriva Therapeutics plc（爱尔兰）
• Spero Therapeutics（美国）
• 雅培（美国）
• F. Hoffmann-La Roche Ltd.（瑞士）
• Mylan NV（美国）
• Teva Pharmaceutical Industries Ltd.（耶路撒冷）
• 赛诺菲（法国）
• 诺华公司（瑞士）
• 太阳制药工业有限公司（孟买）
• 阿拉宾多制药公司（海得拉巴）
• 鲁宾（孟买）
• 盐野义制药株式会社（日本）
• AbbVie Inc.（美国）
• 坎伯兰制药公司（美国）
• 大冢美国制药公司（美国）
• 礼来公司 (美国)

SKU-68113